Precigen Secures 7-Year FDA Orphan Drug Exclusivity for PAPZIMEOS, Strengthening RRP Treatment Landscape

On June 15, Precigen Inc. (NASDAQ:PGEN) announced that the U.S. Food and Drug Administration had granted its precision m...

Read story →